Allergy/Imm Medical News about yellow jacket anaphylaxis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Novel therapies for children with severe asthma

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Analysis of the burden of treatment in patients receiving an EpiPen for yellow jacket anaphylaxis
Journal of Allergy and Clinical Immunology, 09/26/06

Joanne N.G. Oude Elberink MD, et al. - Venom immunotherapy (VIT) is a treatment with established efficacy for the prevention of repeated anaphylactic reactions in patients with Hymenoptera allergy, which also allows patients to discontinue carrying an EpiPen...Conclusion: In contrast to VIT, the EpiPen is perceived as burdensome by most patients with venom allergy. For most patients, an EpiPen is an unsuitable definitive treatment. As VIT enables patients with venom allergy to get rid of the EpiPen, patients should be offered VIT